-
Tafasitamab and Lenalidomide reach the main end of the trial in Phase 2 clinical trials treating Patients with DLBCL
Time of Update: 2020-06-09
DLBCL is the most common non-Hodgkin's lymphoma (NHL) type, accounting for 40% of B-cell NHL It is a rapidly moving NHL type 30-40% of patients did not respond to the initial therapy or relapsed re
-
NICE recommends Alnylam's Onpattro (patisiran) to treat multiple neuropathy caused by amyloid degeneration
Time of Update: 2020-06-09
The National Institute for Health and Clinical Excellence (NICE) has recently issued a positive opinion recommending http:// a drug (http:// http:// at the of the of Alnylam Pharmaceuticals (
-
FDA approves new base Otezla for adult patients to treat mouth ulcers associated with white congestion disease
Time of Update: 2020-06-09
recently, The Administration of food and drugs http:// (http:// has approved Otezla (apremilast) 30mg twice a day (BID) for adult patients to treat mouth ulcers associated with behet's disease
-
The National Drug Administration approves Roche Pharmaceuticals Partett ® joint quto-bead and chemotherapy for new complementary treatment sparing for early breast cancer patients
Time of Update: 2020-06-08
Recently, Roche Pharmaceutical (http:// announced that its breast cancer innovation target drug Partet ® (Perjeta ®, generic name: Patojusmono) has been approved by China's National Drug (http:
-
Stone medicine, Chinese medicine, Yiling, four medicine, Shenwei, Changshan biochemical leading heavyweight debut Shijiazhuang Drug Expo
Time of Update: 2020-06-08
the 13th china Shijiazhuang International Pharmaceutical (http:// (http:// (http:// Expo (the "Pharmaceutical Expo") will be held from October 24 to 26, 2019 at the Shijiazhuang Internation
-
FDA has granted Aeglea's Pegzilarginase Breakthrough Treatment
Time of Update: 2020-06-08
ARG1-D, also known as arginineemia, is a rare genetic disorder Patients due to mutations in the ARG1 gene, resulting in the lack of argininase 1 in the liver, arginine metabolism disorders Aeglea B
-
FDA agrees to PharmaMar to file claim for new drug by Zepsyre ®
Time of Update: 2020-06-08
The u.S Food and drug (http:// Regulatory Authority ( FDA ) has agreed to approve The (http:// application for® a second-line single-drug treatment for small cell lung cancer, the of the F
-
Aliscon SLE reaches major endpoint in phase 3 clinical trial of single anti-drug anifrolumab
Time of Update: 2020-06-08
SLE is an autoimmune disease with a incidence rate of about 30 cases per 100,000 people in China About 90% of SLE patients are female Today, AstraZeneca announced that its , http:// for the treatme
-
FDA approves GlaxoSmithKline Nucala for treatment of pediatric severe eosinophilic granulocytes
Time of Update: 2020-06-08
recently, GlaxoSmithKline (GSK) announced that the U.S Food and Drug (http:// Administration ( FDA (http:// ) has approved Nucala (mepolizumab) for the treatment of severe eosinophilic asthma in
-
FDA grants Provention Bio teplizumab (PRV-031) to prevent or delay type 1 diabetes
Time of Update: 2020-06-08
The immune system of a type 1 diabetes patient mistakenly attacks their own islet beta cells, causing gradual damage to beta cell function and death, and ultimately the patient will need to rely on
-
European Commission grants Bayer's cancer precision treatment drug larotrectinib to market
Time of Update: 2020-06-08
recently, Bayer (http:// announced that the European Commission has granted the European Union a market license for the of the http:// drug for cancer," larotrectinib larotrectinib is suitabl
-
Gene therapy SRP-9003 for beta-myolysis achieves positive results in Phase 1/2a clinical trials
Time of Update: 2020-06-08
Recently, Sarepta Therapeutics (http:// announced positive results in its gene therapy SRP-9003 (MYO-101) for the treatment of beta-myolysis (LGMD2E) in the (http:// of the 1/2a Clinical Trial
-
FDA grants Roche's Vinutuzumab breakthrough drug for lupus nephritis
Time of Update: 2020-06-08
Roche, the giant of Pharmaceuticals (http:// in Switzerland, recently announced that the Authority for food and drugs http:// (http:// has granted Gazyva (obinutuzumab, obituzumab) a breakt
-
FDA grants Brynering Ingeheim's breakthrough therapy designation
Time of Update: 2020-06-08
today, the http:// of the of the of the bouring fdae company announced that the U.S FDA (http:// granted its small molecule tyrosine kinase inhibitor, Ofev (nintedanib), as a breakthrough ther
-
FDA grants Annexon monoclonal antibody ANX005 fast-track qualification
Time of Update: 2020-06-08
GBS is a rare acute autoimmune disease caused by nerve conduction damage caused by the patient's own immune system attacking his peripheral nervous system Today (September 24), annexon Biosciences
-
FDA grants AstraZeneca Farxiga (Dagre Net) rapid-track eligibility for heart failure
Time of Update: 2020-06-08
recently, AstraZeneca announced The FDA (http:// granted its Farxiga (Dagre Net) rapid-track eligibility for heart failure, which is used to reduce the risk of cardiovascular death or hospitaliza
-
NMPA approves Dapeng Pharmaceuticalantiphre anti-cancer drug Lonsurf for treatment of patients with metastatic colorectal cancer
Time of Update: 2020-06-08
Japanese pharmaceutical company Dapeng Pharmaceutical (http:// announced that China's National Medicines (http:// Regulatory Authority (NMPA) has approved the anti-cancer drug Lonsurf (triflur
-
Clinical trial application for Sansheng Pharmaceutical Nafuramorphine Hydrochlorite (TRK-820) approved
Time of Update: 2020-06-08
Recently, Sansheng Pharmaceutical (http:// (01530 HK) announced that its clinical trial (http:// for clinical trials of the drug (http:// for the treatment of itching in hemodialysis patient
-
Green leaf pharmaceutical injection with acetate Gosherrin slow-release microsphere (LY01005) completes a human pharmacokinetic test in the United States
Time of Update: 2020-06-08
prostate cancer and breast cancer are among the most common cancers in the world among men and women, and are on the rise rapidly Recently, Green leaf Pharmaceutical (http:// Group announced tha
-
Scientists develop a new way to fight cancer
Time of Update: 2020-06-08
Recently, University College London published a study that said that some genes that have a "suppressive" effect on tumours are often "shut off" by cancer cells, and the newly discovered methods can
